Clinical Trials Browser

Phase 2 × midostaurin × 90 days × Clear all

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute